BioSpring.Ltd – Healing Beyond Borders
  • Home
  • About Us
  • Our Focus
    • Press Release
    • Global Market
    • Product Pipeline
  • Manufacturing
  • Product Verify
  • Contact Us
  • Home
  • About Us
  • Our Focus
    • Press Release
    • Global Market
    • Product Pipeline
  • Manufacturing
  • Product Verify
  • Contact Us
BioSpring.Ltd > Generic Drug
  • BioSpring Launches BIOMOB to treat EGFR Ex20ins mutated lung cancer for Global Market Clients

    BioSpring Launches BIOMOB to treat EGFR Ex20ins mutated lung cancer for Global Market Clients

    11.07.2022 115 Views

    November 07, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching BIOMOB (Mobocertinib 40mg) capsules for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Ex20ins) mutation. Mobocertinib is a small molecule tyrosine kinase inhibitor. Its molecular target is epidermal growth factor receptor (EGFR) bearing mutations in the exon 20 region.Mobocertinib is an irreversible kinase inhibitor, forming a covalent…

  • BioSpring Launches Oral Psoriasis Therapy BIODEUCRA for Global Market Clients

    BioSpring Launches Oral Psoriasis Therapy BIODEUCRA for Global Market Clients

    10.06.2022 363 Views

    October 06, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching BIODEUCRA (Deucravacitinib 6mg) tablets for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the first approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis…

  • BioSpring launches BIOPALB for HR+/HER2- mBC breast cancer in global market

    BioSpring launches BIOPALB for HR+/HER2- mBC breast cancer in global market

    10.05.2022 185 Views

    October 05, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching BIOPALB (Palbociclib 125mg) capsules are indicated for the treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (mBC) in combination with: an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men, or fulvestrant in patients…

  • BioSpring launches Bioscovy for PrEP in global market

    BioSpring launches Bioscovy for PrEP in global market

    09.20.2022 167 Views

    September 20, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching Bioscovy (emtricitabine 200mg/ tenofovir alafenamide 25mg) tablet for customers, each box of Bioscovy includes 30 tablets. It is a tablet taken by mouth.  Bioscovy for PrEP (pre-exposure prophylaxis) is a once-daily prescription medicine for adults and adolescents at risk of HIV. Bioscovy for PrEP is not for everyone: It is not…

  • BioSpring launches new product packaging for SaiLin’s global market customers

    BioSpring launches new product packaging for SaiLin’s global market customers

    09.14.2022 267 Views

    September 14, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") launches New Product Packaging for SaiLin's Global Market Customers. This product packaging upgrade is to fulfill the previous promise of BioSpring's acquisition of SaiLin, and will continue to provide follow-up support and services to Sailin's global customers. The batch will use Biospring's anti-counterfeiting verification system. Including the following 7 anticancer drug…

  • BioSpring launches new drug Tadazen for customers in global market

    BioSpring launches new drug Tadazen for customers in global market

    09.08.2022 191 Views

    September 08, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching Tadazen (tadalafil) tablet for customers, which will be available in a single strength of 20mg, and each box of tadazen includes 8 tablets.It is a tablet taken by mouth. Onset is typically within half an hour and the duration is up to 36 hours. This product is manufactured and produced by…

  • BioSpring Announces Commercial Packaging Solutions for Formulation manufacturing

    BioSpring Announces Commercial Packaging Solutions for Formulation manufacturing

    09.07.2022 266 Views

    September 07, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") announces coommerical packaging solutions for formulation manufacturing. Completing the prefabrication process for this commercial package ahead of time will help shorten the overall manufacturing cycle. Samuel, founder and CEO of BioSpring, said: “BioSpring can help customers overcome the challenges of formulating, processing and scaling up manufacturing of generic drugs.” Days it takes…

BioSpring.Ltd – Healing Beyond Borders

Our world-class finished dose manufacturing facility is located in the middle of the best industrial development areas in Laos [Saysetteha Development Zone]. The factory has specialized manufacturing modules for oral solid dose tablets, capsules, injections and caters to both export and domestic markets.

  • Our Focus
    • Press Release
    • Global Market
    • Product Pipeline
  • About Us
    • Manufacturing
    • Product Verify
    • Contact Us

Follow Us

  • LienTeh
  • Eeinpresswire

Copyright © 2022. BioSpring.LTD. All rights reserved.

Privacy Policy Terms & Conditions